Prostate Cancer Who needs active surveillance?
|
|
- Jemima Mitchell
- 5 years ago
- Views:
Transcription
1 Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms. Martin Spahn
2 Epidemiologie ? Bray et al Ferlay et al Eurostat 2006
3 Cancer Incidence Rates* for Men, US, Rate Per 100,000 Prostate Colon & rectum Lung & bronchus Urinary bladder Non-Hodgkin lymphoma *Age-adjusted to the 2000 US standard population. Source: Surveillance, Epidemiology, and End Results Program, , Division of Cancer Control and Population Sciences, National Cancer Institute, 2004.
4 N Engl J Med 2009;360: N Engl J Med 2009;360: % No difference Reduction Of mortality PSA cut-off 4.0 ng/ml Sextant biopsies Pre-Screened short Follow up High contamination rate Only 40% biopsies
5 European Randomized Study of Screening for Prostate Cancer (ERSPC) Intention-to-screen analysis: To avoid one PCa death 1410 (95% CI, ) men need to be screened 48 individuals need to be treated radically Overdetection and Overtreatment Schroeder et al. NEJM 2009
6 The diagnosis of low risk PCa is increasing Cooperberg et al, J Urol 2003
7 Rationale for active surveillance 1. Some men with PCa benefit from radical treatment 2. Treatment has adverse effects, and should be given only to those who stand to benefit 3. Most men with screen-detected PCa probably do not need treatment
8 Heidenreich et al., Eur Urol 2011 (59) 61-71
9 Inclusion criteria in Active Surveillance Series Author Publication year Inclusion criteria Treatment criteria Klotz 2006 PSA <15, Gleason <7, <T2b Soloway 2007 Age <80 years, PSA < 15, Gleason <6, < T2, <50% of two biopsy cores Carter 2007 PSA density <0.15ng/ml/cm 3, Gleason <6, <2 positive cores, <50% of any core involved Dall era 2008 PSA < 10, Gleason <6, <33% biopsy, T1/T2a Van As 2008 PSA < 15, Gleason <7, <50% positive biopsy cores (PBC), T1/T2a PSADT < 2 years, clinical progression, biopsy progression PSA progression, re-biopsy <7, stage progression, patient preference Gleason 4 or 5, >2 cores with cancer, >50% cancer in any core on re-biopy Increase in re-biopsy Gleason sum, PSA velocity >0.75ng/mL per year PSA velocity > 1ng/ml/yr, primary Gleason grade >/= 4, or PBC >50% on repeat biopsy Roemeling 2007 Screen detected As per clinician / patient decision
10 Results of Active Surveillance Author n Median age (years) Follow-up (Months) % remaining on surveillance Cancer specific mortality (%) Klotz 299 Not given Soloway Carter Dall era Van As Roemeling
11 Active Surveillance with delayed treatment - Cancer specific survival - Klotz et al., J. Urol., 172:S48-S51, 2004
12 Active Surveillance ERSPC P = Delayed RP Immediate RP Van den Bergh et al., Cancer 2010;116:
13 Natural course of Pca Albertsen tables N=767 Diagnosed Clinical stage T2 Palliative treatment Dark grey = PCa Light grey = nonpca White = survival Albertsen et al., JAMA,1995 (8):
14 Distribution Gleason Score 50% 40% Orginal Actual Percentag ge of Men 30% 20% 10% 0% Gleason Score N = 1858 men Albertsen et al. J Natl Cancer Inst 97: , 2005
15 Natural course of Pca N= Diagnosed Clinical stage T2 Conservative treatment Dark grey = PCa Light grey = nonpca White = survival Lu-Yao et al., JAMA,2009 (11):
16 Prostate cancer Median age at diagnosis: 68 yrs. 1 out of 4 PCa patients >75 yrs. 71% of all PCa deaths Ries L et al. SEER Cancer Statistics Review,
17 Life Expectancy In 2002 Age Expected Lifetime (years) Statistisches Bundesamt 2004
18 Prevalence of comorbidity across age groups Piccirillo et al. Critical Reviews Oncology-Hematology 2008;67(2):
19 Estimates of Life Expectancy Walter et al. JAMA 2001; 285:
20 Competing risk of mortality by age at diagnosis, cancer stage, grade, and comorbidity: cancer stage T2. Albertsen et al. JCO 2011;29:
21 Natural history of prostate cancer Prostate cancer is inherently biologically heterogenous Patients have been staged differently in various studies Stage N 15 year PFS 15 year DSS % 95% CI % 95% CI T1-T T3-T M Johansson et al., JAMA,1997;227:
22 Who needs active surveillance? PSA <15, Gleason <7, <T2b Age <80 years, PSA < 15, Gleason <6, < T2, <50% of two biopsy cores PSA density <0.15ng/ml/cm3, Gleason <6, <2 positive cores, <50% of any core involved PSA < 10, Gleason <6, <33% biopsy, T1/T2a PSA < 15, Gleason <7, <50% positive biopsy cores (PBC), T1/T2a Screen detected
23 Who needs active surveillance? - Future aspects - Men with low risk PCa criteria Men with intermediate risk PCa and Charlson score >1 Men >75 yrs. of age Men ineligible for definitive local radical treatment
PSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationMen at risk of prostate cancer. Recommendation D C. Reevaluating PSA Testing in the PLCO Trial. already in 2012
Men at risk of prostate cancer a) «The wind has changed» :USPSTF Früherkennung und Diagnostik des Prostatakarzinoms Prof. Dr. med. Franz Recker Senior Consultant Kantonsspital Aarau Stiftung Prostatakrebsforschung
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 101 107 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Laurence Klotz on pp. 108 110 of this issue
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More informationProstate Cancer: from Beginning to End
Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationAUA Update Series. Lesson 33 Volume Active Surveillance for Prostate Cancer: Patient Selection and Management
AUA Update Series Lesson 33 Volume 27 2008 Active Surveillance for Prostate Cancer: Patient Selection and Management Learning Objective: At the conclusion of this continuing medical education activity,
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationProstate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto
Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA
More informationYiannis Philippou 1, Hary Raja 2 and Vincent J. Gnanapragasam 2*
Philippou et al. BMC Urology (2015) 15:52 DOI 10.1186/s12894-015-0049-y RESEARCH ARTICLE Open Access Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and
More informationeuropean urology 51 (2007)
european urology 51 (2007) 366 374 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate
More informationPredicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance
european urology 54 (2008) 1297 1305 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Predicting the Probability of Deferred Radical Treatment for Localised
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION LESS IS MORE Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4. ng/ml Yu-Hsuan Shao, PhD; Peter C.
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationLocal Recommendations for Active Surveillance of Prostate Cancer
February 15 Local Recommendations for Active Surveillance of Prostate Cancer Chris Dawson Urology Lead Clinician February 2015 www.pchurology.co.uk Summary and Recommendations 1. There is no single set
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationOtis W. Brawley, MD, MACP, FASCO, FACE
Otis W. Brawley, MD, MACP, FASCO, FACE Chief Medical and Scientific Officer American Cancer Society Professor of Hematology, Medical Oncology, Medicine and Epidemiology Emory University Atlanta, Georgia
More informationActive Surveillance for Prostate Cancer: A Systematic Review of the Literature
EUROPEAN UROLOGY 62 (2012) 976 983 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Prostate Cancer Editorial by Gurdarshan S. Sandhu
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationOli-P and beyond Endpoints for PSMA based local ablative Radiotherapy. Dr. med. Fabian Lohaus Klinik und Poliklinik für Radioonkologie der TU Dresden
Oli-P and beyond Endpoints for PSMA based local ablative Radiotherapy Dr. med. Fabian Lohaus Klinik und Poliklinik für Radioonkologie der TU Dresden Conflicts of interest none 1. The natural course of
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME NUMBER 20 JULY 10 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance Sima P. Porten, Jared M. Whitson,
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationActive surveillance: Shrinking the grey zone. Sommerakademi e Munich, June rd FOIUS Tel Aviv, July 2016
Active surveillance: Shrinking the grey zone Active surveillance: 3 rd FOIUS Tel Aviv, July 2016 Shrinking the grey zone Sommerakademi e Munich, June 30 2016 Active Surveillance for low risk PCa What has
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationApproximately 680,000 men are diagnosed with prostate
Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram E. W. Steyerberg,* M. J. Roobol, M. W. Kattan, T. H. van der Kwast, H. J. de Koning and F. H. Schröder From the
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
ORIGINAL ARTICLE (2011) 14, 53 57 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan Relationship between initial PSA density with future PSA kinetics and repeat biopsies
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationSHARED DECISION MAKING FOR PROSTATE CANCER SCREENING
SHARED DECISION MAKING FOR PROSTATE CANCER SCREENING 16 TH A N N U A L M A S S A C H U S E T T S P R O S T A T E C A N C E R S Y M P O S I U M Mary McNaughton-Collins, MD, MPH Foundation Medical Director
More informationOutcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study
JNCI Journal of the National Cancer Institute Advance Access published June 18, 2010 DOI: 10.1093/jnci/djq154 Article The Author 2010. Published by Oxford University Press. This is an Open Access article
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationManaging Prostate Cancer in General Practice
Managing Prostate Cancer in General Practice Tuesday 18 th September 2018 Presenters: Prof Jon Emery Assoc Prof Declan Murphy The education has been developed in partnership with Cancer Council Victoria,
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
An Exploration of Risk Stratification for Active Surveillance and Androgen Deprivation Therapy Side Effects for Prostate Cancer Utilizing Data From the Surveillance, Epidemiology, and End Results Database
More informationOutcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better
1 sur 5 19/09/2009 07:02 www.medscape.com From Medscape Medical News Outcomes With "Watchful Waiting" in Prostate Cancer in US Now So Good, Active Treatment May Not Be Better Zosia Chustecka September
More informationThe Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017
The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA
More informationCan men on AS be treated with testosterone?
Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationActive surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationActive Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof?
Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Duke Bahn MD Prostate Institute of America, Ventura, California INTRODUCTION In the November
More informationOriginal Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men 50 years
Am J Clin Exp Urol 2014;2(4):332-336 www.ajceu.us /ISSN:2330-1910/AJCEU0002941 Original Article The implications of prostate-specific antigen density to predict clinically significant prostate cancer in
More informationFollow-up of Prostatectomy versus Observation for Early Prostate Cancer
The new england journal of medicine Original Article Follow-up of Prostatectomy versus Observation for Early Prostate Cancer Timothy J. Wilt, M.D., M.P.H., Karen M. Jones, M.S., Michael J. Barry, M.D.,
More informationPCA MORTALITY VS TREATMENTS
PCA MORTALITY VS TREATMENTS Terrence P McGarty White Paper No 145 July, 2017 In a recent NEJM paper the authors argue that there is no material difference between a prostatectomy and just "observation"
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationActive Surveillance (AS) is an expectant management. Health Services Research
Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer Health Services Research Jianyu Liu, Paul R. Womble, Selin Merdan, David C. Miller, James E. Montie, Brian T. Denton on
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationProstate Cancer Screening. Dickon Hayne University of Western Australia
Prostate Cancer Screening Dickon Hayne University of Western Australia JMG Wilson & G Junger, WHO, 1968 p26-27 In theory, therefore, screening is an admirable method of combating disease, since it should
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationCancer Screening 2009: New Tests, New Choices
Objectives Cancer Screening 2009: New Tests, New Choices UCSF Annual Review in Family Medicine April 21, 2009 Michael B. Potter, MD Professor, Clinical Family and Community Medicine UCSF School of Medicine
More informationReducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study
Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher
More informationThe Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance
EUROPEAN UROLOGY 56 (2009) 891 898 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Nazareno Suardi on pp. 899 900 of this issue
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationImpact of PSA Screening on Prostate Cancer Incidence and Mortality in the US
Impact of PSA Screening on Prostate Cancer Incidence and Mortality in the US Deaths per 100,000 Ruth Etzioni Fred Hutchinson Cancer Research Center JASP Symposium, Montreal 2006 Prostate Cancer Incidence
More informationResponse to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners
Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More information